特立帕肽相关钙化防御:病例系列分析
本文通过检索文献和FDA不良事件报告系统,分析了12例特立帕肽相关钙化防御病例。患者中位年龄81岁,中位发病时间3.5个月,所有病例均存在多重风险因素。提示特立帕肽暴露可能与潜在风险因素共同触发钙化防御,需早期诊断干预。
要点
- 特立帕肽相关钙化防御罕见但可能致命,中位发病时间3.5个月。
- 所有病例均存在多重风险因素,包括合并用药、女性、自身免疫病等。
- 早期诊断和干预可能改善预后,临床需警惕。
核心结论
- 特立帕肽暴露与潜在风险因素共同可能触发新发钙化防御。
研究设计与样本
- 通过检索EMBASE、PubMed文献及FDA不良事件报告系统(截至2021年3月31日),纳入特立帕肽暴露<2年的钙化防御病例。
主要发现
- 共报告12例特立帕肽相关钙化防御,中位年龄81岁(范围47-86)。
- 11例有活检和/或影像学确认,中位发病时间3.5个月(范围1-20)。
- 3例住院,其中1例因病变进展死亡;所有病例均有多种风险因素(平均4.5,SD 1.0)。
关键数值与推荐
- 风险因素包括合并使用与钙化防御相关药物(12例)、女性(11例)、自身免疫病或其他炎症性疾病(10例)。
临床怎么用
- 对使用特立帕肽的患者,尤其存在多重风险因素者,应警惕钙化防御,早诊早治。
局限性
- 病例系列基于自发报告,可能存在报告偏倚和混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Calciphylaxis is a rare and potentially fatal small-vessel occlusive disease in which the tunica media becomes calcified, endothelial cells proliferate, and the tunica intima becomes thickened and fibrotic. Calciphylaxis typically occurs in the setting of end-stage renal disease with secondary hyperparathyroidism and elevated calcium-phosphorus product. The estimated incidence of calciphylaxis in dialysis or kidney transplant patients is 1 to 4%; however, the incidence of non-uremic calciphylaxis is unknown. We assessed postmarketing adverse event reports to further characterize cases of calciphylaxis associated with teriparatide. We searched for cases of teriparatide-associated calciphylaxis in the literature (EMBASE, PubMed) and those reported to FDA, including the FDA Adverse Event Reporting System, through March 31, 2021. We included calciphylaxis cases following teriparatide exposure of < 2 years. Twelve cases described teriparatide-associated calciphylaxis. The median age was 81 (range 47-86) years. Eleven cases reported confirmatory biopsy and/or imaging. The median time-to-onset of calciphylaxis following teriparatide initiation was 3.5 (range 1-20) months. Three cases reported hospitalization, of which one resulted in death due to progression of the lesions. All cases had multiple risk factors (mean (SD), 4.5 (1.0)) including concomitant medications associated with calciphylaxis (12), female sex (11), and/or underlying autoimmune disease or other inflammatory disorder (10). We believe that exposure to teriparatide, coupled with underlying risk factors, may have triggered new-onset calciphylaxis. Expedited diagnosis and management by a clinician are important because calciphylaxis may be life-threatening and early intervention may improve outcomes.
引用
- Kim J, Konkel K, Jones SC, et al. Teriparatide-associated calciphylaxis: a case series. Osteoporos Int. 2021. PMID: 34494145. doi:10.1007/s00198-021-06139-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。